TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07595003: Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of 4-MUST, 128 mg Tablets in Patients With Chronic Cholecystitis and Biliary Tract Dyskinesia

Sponsor: Valenta Pharm JSC · Phase: PHASE3 · Area: DERMATOLOGY_AESTHETIC · Target Enrollment: 300 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$6,997,476

Rescue Site Savings

+$4,616,136

Unlock Full NCT07595003 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07595003 Rescue Dossier →